How can we help?


Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.


Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).


Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.


Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.


Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.


The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products


In Situ Hybridization Protocols - New book published
Boye Schnack Nielsen, R&D Manager in Molecular Histology at Bioneer, has been the editor of a newly published book with the title: In Situ Hybridization Protocols.

For more information about the book press this link
Read more
CarTarDis project - latest articel
Bioneer is a partner in the EU funded CarTarDis (Cardiovascular Target Discovery) consortium ( or press this link.
The CarTarDis consortium is a private public consortium and the goal is to advance the development of cardiovascular disease medicines by discovery and validation of novel therapeutics targets to cardiovascular disease.
Read more
Read ALL news

Ongoing inNovation consortia:

A Danish initiative to enhance our understanding of the complexity of cancer diseases.
Read more

Meet us at:

Bioneer:FARMA will organize a workshop at AAPS in San Diego
Bioneer:FARMA will organize a workshop: Improving Oral Bioavailability by Lipid-Based Delivery
Read more
miRNA Diagnostic meeting in Boston 28-30 October
Bioneer will participate and present at the annual meeting on the topic "discovery and pre-clinical, diagnostic and therapeutic applications of miRNAs".
The conference will be held in Boston, USA, October 28-30, 2014
Read more
AAPS 2014 November 2-6 in San Diego
Bioneer will participate and present at the annual AAPS meeting held in San Diego, USA, from Nov 2-6.
Read more
BIO-Europe 2014 in Frankfurt
Bioneer will participate and present at this year BIO-Europe held in Frankfurt from the 3-5 of November.
Read more
Other places to meet us